|
1
|
Stahl M and Tallman MS: Acute
promyelocytic leukemia (APL): Remaining challenges towards a cure
for all. Leuk Lymphoma. 60:3107–3115. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Su R, Qing Y and Chen J: Targeting
differentiation blockade in AML: New hope from cell-surface-based
CRISPR screens. Cell Stem Cell. 28:585–587. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
He Y, Hara H and Núñez G: Mechanism and
regulation of NLRP3 inflammasome activation. Trends Biochem Sci.
41:1012–1021. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martinon F, Burns K and Tschopp J: The
inflammasome: A molecular platform triggering activation of
inflammatory caspases and processing of proIL-beta. Mol Cell.
10:417–426. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vince JE and Silke J: The intersection of
cell death and inflammasome activation. Cell Mol Life Sci.
73:2349–2367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gaidt MM and Hornung V: The NLRP3
inflammasome renders cell death Pro-inflammatory. J Mol Biol.
430:133–141. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zheng M, Williams EP, Malireddi RKS, Karki
R, Banoth B, Burton A, Webby R, Channappanavar R, Jonsson CB and
Kanneganti TD: Impaired NLRP3 inflammasome activation/pyroptosis
leads to robust inflammatory cell death via caspase-8/RIPK3 during
coronavirus infection. J Biol Chem. 295:14040–14052. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hamarsheh S, Osswald L, Saller BS, Unger
S, De Feo D, Vinnakota JM, Konantz M, Uhl FM, Becker H, Lübbert M,
et al: Oncogenic KrasG12D causes myeloproliferation via
NLRP3 inflammasome activation. Nat Commun. 11:16592020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Q, Hua M, Zhang C, Wang R, Liu J, Yang
X, Han F, Hou M and Ma D: NLRP3-activated bone marrow dendritic
cells play antileukemic roles via IL-1β/Th1/IFN-γ in acute myeloid
leukemia. Cancer Lett. 520:109–120. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sauter KA, Wood LJ, Wong J, Iordanov M and
Magun BE: Doxorubicin and daunorubicin induce processing and
release of interleukin-1β through activation of the NLRP3
inflammasome. Cancer Biol Ther. 11:1008–1016. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Westbom C, Thompson JK, Leggett A,
MacPherson M, Beuschel S, Pass H, Vacek P and Shukla A:
Inflammasome modulation by chemotherapeutics in malignant
mesothelioma. PLoS One. 10:e01454042015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Myou S, Zhu X, Boetticher E, Qin Y, Myo S,
Meliton A, Lambertino A, Munoz NM, Hamann KJ and Leff AR:
Regulation of adhesion of AML14.3D10 cells by surface clustering of
beta2-integrin caused by ERK-independent activation of cPLA2.
Immunology. 107:77–85. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lam CF, Yeung HT, Lam YM and Ng RK:
Reactive oxygen species activate differentiation gene transcription
of acute myeloid leukemia cells via the JNK/c-JUN signaling
pathway. Leuk Res. 68:112–119. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yates JW, Wallace HJ Jr, Ellison RR and
Holland JF: Cytosine arabinoside (NSC-63878) and daunorubicin
(NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer
Chemother Rep. 57:485–488. 1973.PubMed/NCBI
|
|
17
|
Lo-Coco F, Avvisati G, Vignetti M, Thiede
C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona
E, et al: Retinoic acid and arsenic trioxide for acute
promyelocytic leukemia. N Engl J Med. 369:111–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Swanson KV, Deng M and Ting JP: The NLRP3
inflammasome: Molecular activation and regulation to therapeutics.
Nat Rev Immunol. 19:477–489. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang Y, Xu W and Zhou R: NLRP3
inflammasome activation and cell death. Cell Mol Immunol.
18:2114–2127. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heid ME, Keyel PA, Kamga C, Shiva S,
Watkins SC and Salter RD: Mitochondrial reactive oxygen species
induces NLRP3-dependent lysosomal damage and inflammasome
activation. J Immunol. 191:5230–5238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sorbara MT and Girardin SE: Mitochondrial
ROS fuel the inflammasome. Cell Res. 21:558–560. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Coll RC, Robertson AA, Chae JJ, Higgins
SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG,
Stutz A, et al: A small-molecule inhibitor of the NLRP3
inflammasome for the treatment of inflammatory diseases. Nat Med.
21:248–255. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sharma BR and Kanneganti TD: NLRP3
inflammasome in cancer and metabolic diseases. Nat Immunol.
22:550–559. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo B, Fu S, Zhang J, Liu B and Li Z:
Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci
Rep. 6:361072016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Drexler SK, Bonsignore L, Masin M,
Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp
J and Yazdi AS: Tissue-specific opposing functions of the
inflammasome adaptor ASC in the regulation of epithelial skin
carcinogenesis. Proc Natl Acad Sci USA. 109:18384–18389. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dunn JH, Ellis LZ and Fujita M:
Inflammasomes as molecular mediators of inflammation and cancer:
potential role in melanoma. Cancer Lett. 314:24–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Daley D, Mani VR, Mohan N, Akkad N,
Pandian GSDB, Savadkar S, Lee KB, Torres-Hernandez A, Aykut B,
Diskin B, et al: NLRP3 signaling drives macrophage-induced adaptive
immune suppression in pancreatic carcinoma. J Exp Med.
214:1711–1724. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ghiringhelli F, Apetoh L, Tesniere A,
Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G,
Ullrich E, et al: Activation of the NLRP3 inflammasome in dendritic
cells induces IL-1beta-dependent adaptive immunity against tumors.
Nat Med. 15:1170–1178. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dupaul-Chicoine J, Arabzadeh A, Dagenais
M, Douglas T, Champagne C, Morizot A, Rodrigue-Gervais IG, Breton
V, Colpitts SL, Beauchemin N and Saleh M: The Nlrp3 inflammasome
suppresses colorectal cancer metastatic growth in the liver by
promoting natural killer cell tumoricidal activity. Immunity.
43:751–763. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huber S, Gagliani N, Zenewicz LA, Huber
FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O'Connor W Jr, Murphy AJ, et
al: IL-22BP is regulated by the inflammasome and modulates
tumorigenesis in the intestine. Nature. 491:259–263. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
van Deventer HW, Burgents JE, Wu QP,
Woodford RM, Brickey WJ, Allen IC, McElvania-Tekippe E, Serody JS
and Ting JP: The inflammasome component NLRP3 impairs antitumor
vaccine by enhancing the accumulation of tumor-associated
myeloid-derived suppressor cells. Cancer Res. 70:10161–10169. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Karki R and Kanneganti TD: Diverging
inflammasome signals in tumorigenesis and potential targeting. Nat
Rev Cancer. 19:197–214. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang J, Liu L, Xie L, Xiang G and Zhou Y:
Induction of differentiation-specific miRNAs in TPA-induced myeloid
leukemia cells through MEK/ERK activation. Int J Mol Med. 31:59–66.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Daigneault M, Preston JA, Marriott HM,
Whyte MK and Dockrell DH: The identification of markers of
macrophage differentiation in PMA-stimulated THP-1 cells and
monocyte-derived macrophages. PLoS One. 5:e86682010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maeß MB, Wittig B, Cignarella A and
Lorkowski S: Reduced PMA enhances the responsiveness of transfected
THP-1 macrophages to polarizing stimuli. J Immunol Methods.
402:76–81. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Park EK, Jung HS, Yang HI, Yoo MC, Kim C
and Kim KS: Correction to: Optimized THP-1 differentiation is
required for the detection of responses to weak stimuli. Inflamm
Res. 69:11572020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Aldo PB, Craveiro V, Guller S and Mor G:
Effect of culture conditions on the phenotype of THP-1 monocyte
cell line. Am J Reprod Immunol. 70:80–86. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Faria SS, Costantini S, de Lima VCC, de
Andrade VP, Rialland M, Cedric R, Budillon A and Magalhães KG:
NLRP3 inflammasome-mediated cytokine production and pyroptosis cell
death in breast cancer. J Biomed Sci. 28:262021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Teng JF, Mei QB, Zhou XG, Tang Y, Xiong R,
Qiu WQ, Pan R, Law BY, Wong VK, Yu CL, et al: Polyphyllin VI
induces Caspase-1-mediated pyroptosis via the induction of
ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell lung cancer.
Cancers (Basel). 12:1932020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xia X, Wang X, Cheng Z, Qin W, Lei L,
Jiang J and Hu J: The role of pyroptosis in cancer: pro-cancer or
pro-‘host’ ? Cell Death Dis. 10:6502019. View Article : Google Scholar : PubMed/NCBI
|
